C01AA05 - Digoxin |
Not porphyrinogenic |
NP |
Rationale
Not CYP-metabolised. No data pointing to induction or inhibition of CYPs. Several references state non- porphyrinogenicity. The daily dose is beneath the mg range and hepatocyte exposure beneath the micromolar range.
Therapeutic characteristics
Heart glycoside used in cardiac insufficiency and cardiac arrythmias.
Hepatic exposure
The daily dose is beneath the mg range and hepatocyte exposure beneath the micromolar range.
Metabolism and pharmacokinetics
Although digoxin is reported to be excreted mainly unchanged in the urine there is evidence to suggest that metabolism may sometimes be extensive. Metabolites that have been detected in the urine include digoxigenin, dihydrodigoxigenin, the mono- and bisdigitoxosides of digoxigenin, and dihydrodigoxin. The metabolism of digoxin is not dependent upon the cytochrome P-450 system. Digoxin is not known to induce or inhibit the cytochrome P-450 system.
Personal communication
Andersson, clinical observation (n=1) tolerated.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
References
- Scientific articles
- Moore MR, Hift RJ: Drugs in the acute porphyrias, Cell Mol Biol 43:89, 1997: safe. #1185
- Mikolaenko I, Conner MG. Pathologic quiz case: A 35-year-old woman with a history of arrhythmia and liver failure. Archives of Pathology & Laboratory Medicine 2002; 126(6):751-752. #1186
Similar drugs
© NAPOS 2024